Advanced Comprehensive Laboratory

Advanced Comprehensive Laboratory was paid $2.66M by Medicaid between Mar 2020 and Dec 2024, across 101 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 35% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New Jersey

Rank by total paid#49 of 122

Median peer was paid$1.29M

This provider vs. median2.1×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	3,960	$20K
2021	96,118	$264K
2022	145,828	$1.16M
2023	97,797	$593K
2024incomplete	23,331	$617K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	35%	39,735	10,500	$941K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	27%	25,424	12,578	$714K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	21%	40,649	15,085	$562K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	7.9%	26,520	8,417	$211K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	2.4%	22,878	5,691	$64K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	1.4%	15,157	3,889	$38K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.2%	1,392	931	$31K
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	42,057	10,701	$17K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	1,558	322	$14K
86769		<1%	2,440	375	$9K
80061	Lipid panel	<1%	9,175	2,441	$8K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	3,510	977	$6K

89 more codes

82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	5,687	$5K
80053	Comprehensive metabolic panel	<1%	9,171	$3K
84439		<1%	4,499	$3K
84443	Thyroid stimulating hormone (TSH)	<1%	6,975	$3K
83036	Hemoglobin; glycosylated (A1C)	<1%	8,658	$3K
82607		<1%	4,250	$2K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	12,733	$2K
82746		<1%	3,589	$1K
87486		<1%	1,560	$1K
87581		<1%	1,560	$1K
36415	Collection of venous blood by venipuncture	<1%	13,186	$1K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	33	$1K
82652		<1%	223	$1K
82728		<1%	1,585	$1K
84153		<1%	787	$809.43
84481		<1%	2,032	$745.69
86800		<1%	1,940	$721.79
86235		<1%	138	$715.02
80048	Basic metabolic panel (calcium, ionized)	<1%	1,631	$679.34
84154		<1%	508	$669.80
81001		<1%	5,075	$582.46
87086	Culture, bacterial; quantitative colony count, urine	<1%	1,056	$545.31
82570		<1%	6,120	$464.04
86376		<1%	1,954	$430.93
83550		<1%	1,392	$399.12
83540		<1%	1,751	$352.20
86141		<1%	465	$343.20
82784		<1%	241	$336.50
82668		<1%	125	$317.47
82043		<1%	655	$281.83
84480		<1%	2,741	$277.04
86160		<1%	136	$271.20
86225		<1%	137	$210.01
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	268	$194.86
86256		<1%	138	$189.46
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	309	$185.28
84550		<1%	1,947	$183.58
86696		<1%	271	$178.80
86200		<1%	137	$165.76
84146		<1%	175	$165.26
86803		<1%	450	$165.08
85651		<1%	2,041	$156.34
84403		<1%	182	$152.78
86038		<1%	378	$150.07
86706		<1%	424	$145.43
84410		<1%	124	$126.34
87340		<1%	446	$125.13
84270		<1%	182	$115.79
86695		<1%	265	$111.72
86255		<1%	137	$111.04
84436		<1%	2,722	$92.13
83655		<1%	604	$90.00
81003		<1%	4,340	$85.20
86431		<1%	330	$81.04
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	272	$80.86
84132		<1%	448	$78.96
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	248	$66.72
84450		<1%	849	$57.00
84460		<1%	849	$57.00
87634		<1%	1,668	$56.26
86060		<1%	137	$56.24
86704		<1%	265	$52.23
82310		<1%	448	$50.03
81002		<1%	4,313	$46.17
82040		<1%	1,272	$44.55
85045		<1%	116	$41.19
86708		<1%	264	$40.18
86304		<1%	24	$39.65
85730		<1%	61	$39.62
85610		<1%	61	$36.86
86703		<1%	308	$36.00
82465		<1%	304	$24.00
84156		<1%	399	$22.60
82248		<1%	71	$16.50
82378		<1%	31	$15.17
86705		<1%	45	$13.88
86709		<1%	45	$13.28
83721		<1%	463	$10.66
86140		<1%	124	$9.00
83735		<1%	69	$6.57
84479		<1%	1,764	$6.34
84075		<1%	768	$3.60
82247		<1%	768	$3.00
84155		<1%	768	$1.80
80164		0%	93	$0.00
83718		0%	296	$0.00
83789		0%	47	$0.00
84478		0%	296	$0.00
84402		0%	122	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialFRENKEL, VICTORIA (CEO)